Patients with
chronic inflammatory demyelinating polyradiculoneuropathy (
CIDP) show varying degrees of response to
intravenous immunoglobulin (
IVIg)
therapy. This randomised phase III study in patients with
CIDP (ProCID trial) will compare the efficacy and safety of 3 different doses (0.5, 1.0, and 2.0 g/kg) of
IVIg 10% (
panzyga) administered every 3 weeks for 24 weeks. The primary efficacy endpoint is the rate of treatment response, defined as a decrease in adjusted inflammatory neuropathy cause and treatment disability score of ≥1 point, in the
IVIg 1.0 g/kg arm at week 24. Patients with definite or probable
CIDP according to European Federation of Neurological Sciences/Peripheral Nerve Society criteria with
IVIg or
corticosteroid dependency and active disease are eligible. All potentially eligible patients will undergo
IVIg or
corticosteroid dose reduction (washout phase) over ≤12 weeks or until deterioration of
CIDP (active disease). Patients with deterioration during the washout phase will be randomised to receive study treatment during a dose-evaluation phase starting with a loading dose of
IVIg 2.0 g/kg followed by maintenance treatment with
IVIg 0.5, 1.0, or 2.0 g/kg every 3 weeks. Rescue medication (2 doses of
IVIg 2.0 g/kg given 3 weeks apart) will be administered to patients in the
IVIg 0.5 and 1.0 g/kg groups who deteriorate after week 3 and before week 18 or who do not improve at week 6. Safety, tolerability and quality of life will be assessed. The ProCID study will provide new information on the best maintenance dose of
IVIg for patients with
CIDP.